lutetium has been researched along with Thrombopenia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, YI; Lee, DY | 1 |
| Bruchertseifer, F; Hlongwa, KN; Knoesen, O; Lawal, IO; Mahapane, J; Maserumule, LC; Mdlophane, A; Mokoala, KMG; Morgenstern, A; Ndlovu, H; Popoola, GO; Reed, JD; Sathekge, MM; Vorster, M | 1 |
| Boerman, OC; Boers-Sonderen, MJ; Desar, IM; Langenhuijsen, JF; Mulder, SF; Mulders, PF; Muselaers, CH; Oosterwijk, E; Oyen, WJ; Stillebroer, AB; van Herpen, CM; van Oostenbrugge, TJ | 1 |
| Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabhajosula, S | 1 |
2 review(s) available for lutetium and Thrombopenia
| Article | Year |
|---|---|
Effects of
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Leukopenia; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Thrombocytopenia; Treatment Outcome; Xerostomia | 2022 |
Hematologic toxicity profile and efficacy of [
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kidney Diseases; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2022 |
2 trial(s) available for lutetium and Thrombopenia
| Article | Year |
|---|---|
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Lutetium; Neutropenia; Non-Randomized Controlled Trials as Topic; Radioimmunotherapy; Radioisotopes; Retreatment; Thrombocytopenia | 2016 |
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
Topics: Antibodies, Monoclonal; Blood Platelets; Bone Marrow; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Lutetium; Male; Maximum Tolerated Dose; Prostate-Specific Antigen; Prostatic Neoplasms; Radioimmunotherapy; Radioisotopes; Thrombocytopenia; Time Factors; Yttrium Radioisotopes | 2005 |